Spruce Biosciences Inc expected to post a loss of 29 cents a share - Earnings Preview

Spruce Biosciences

10/05/2024 16:58

* Spruce Biosciences Inc  SPRB.OQ   SPRB.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 13
(estimated) for the period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 41.0% decrease in revenue to $1.158 million from $1.96
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Spruce Biosciences Inc
is for
a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Spruce
Biosciences Inc is $2.50​, above​ its last closing price
of $0.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.39       -0.39      -0.24     Beat    37.8
 Sep. 30 2023  -0.36       -0.35      -0.30     Beat    15.1
 Jun. 30 2023  -0.39       -0.39      -0.32     Beat    18.4​
 Mar. 31 2023  -0.33       -0.36      -0.40     Missed  -10.4
 ​​Dec.        -0.56       -0.53      -0.47     Beat    11.3
 31 2022                                                
 Sep. 30 2022  -0.54       -0.53      -0.48     Beat    10.3​
 Jun. 30 2022  -0.53       -0.52      -0.51     Beat    2.9
 Mar. 31 2022  -0.46       -0.46      -0.50     Missed  -9.1
 This summary was machine generated May 10 at 15:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)